Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Linezolid injection.
The injection is an anti-infective and is used to treat infections caused by susceptibl gram-positive bacteria in specific conditions, the Hyderabad-based company said in a release issued here on Monday.
The approved Abbreviated New Drug Application (ANDA) is a bio-equivalent and is therapeutically equivalent to reference listed drug product Zyvox injection of Pharmacia & Upjohn Company.
The product, which is expected to be launched in the current quarter, has an estimated market size of $87 million for the 12 months ending June 2016, according to IMS.
Aurobindo’s scrip gained 0.63 per cent and was trading at Rs 774.95 on the BSE on Monday.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.